ArticleERJ open research2024
The many faces of COPD in real life: a longitudinal analysis of the NOVELTY cohort.
Article in ERJ open research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02760329 (A NOVEL Observational longiTudinal studY on Patients With Asthma and/or COPD to Describe Patient Characteristics, Treatment Patterns and the Burden of Illness Over Time and to Identify Phenotypes and Endotypes.), which is not on this map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A NOVEL Observational longiTudinal studY on Patients With Asthma and/or COPD to Describe Patient Characteristics, Treatment Patterns and the Burden of Illness Over Time and to Identify Phenotypes and Endotypes.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Prevalence of preserved ratio impaired spirometry and restrictive spirometry pattern in the general population: a systematic review and multi-level meta-analysis of studies from multiple countries.Journal of global health · 2026Pooled it
- Comprehensive application of artificial intelligence in preserved ratio impaired spirometry: A systematic literature review.PloS one · 2026Pooled it
- Clinical and Radiological Characteristics of Symptomatic Emphysema Patients with PRISm and Pre-COPD Phenotypes: Possible Effects of Smoking Status.Biomedicines · 2026Article
- Beyond spirometry: understanding COPD origins to support a new diagnostic approach.ERJ open research · 2026Review
- Multimodal data-driven multitask learning for enhanced identification and classification of chronic obstructive pulmonary disease: a retrospective study.Journal of global health · 2026Article
- Longitudinal Outcomes and Prognostic Risk of Normalized Airflow Obstruction in a Korean General Population Cohort.International journal of chronic obstructive pulmonary disease · 2026Article
- Clinical characteristics and outcomes associated with preserved ratio impaired spirometry (PRISm) in Saudi Arabia.Frontiers in medicine · 2026Article
- Small Airway Disease in Pre-COPD and Early COPD: Insights Into the Pulmonary "Silent Zone".International journal of chronic obstructive pulmonary disease · 2026Review
- Prevalence and associated factors for COPD and pre-COPD in Guizhou Province, China: A cross-sectional study.Tobacco induced diseases · 2026Article
- PulmoClass-3DAtt: A Self-Attention Network for Classification of COPD, PRISm and Normal.International journal of chronic obstructive pulmonary disease · 2026Article
- Air pollution and dynamic transitions of preserved ratio impaired spirometry in UK Biobank.Communications medicine · 2025Article
- Acknowledging the syndemic: a real-life cohort study of major adverse cardiovascular events in COPD.ERJ open research · 2025Article
- Chest CT imaging for differentiating normal, PRISm, and COPD in comparison with pulmonary function tests.La Radiologia medica · 2025Article
- Article
- Towards early detection and disease interception of COPD across the lifespan.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Risk of exacerbations, hospitalisation, and mortality in adults with physician-diagnosed chronic obstructive pulmonary disease with normal spirometry and adults with preserved ratio impaired spirometry in Sweden: retrospective analysis of data from a nationwide cohort study.The Lancet regional health. Europe · 2025Article
- Prevalence, diagnostic accuracy, and healthcare utilization patterns in patients with COPD in primary healthcare: a population-based study.NPJ primary care respiratory medicine · 2025Review
- Associated Factors and Pulmonary Function Outcomes of Preserved Ratio Impaired Spirometry: A Scoping Review.International journal of chronic obstructive pulmonary disease · 2025Article
- Of Mucus and Microbes: The Sticky Issue of Mucin-Microbiome Interactions in Chronic Obstructive Pulmonary Disease.American journal of respiratory and critical care medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The diagnosis of COPD requires the demonstration of non-fully reversible airflow limitation by spirometry in the appropriate clinical context. Yet, there are patients with symptoms and relevant exposures suggestive of COPD with either normal spirometry (pre-COPD) or preserved ratio but impaired spirometry (PRISm). Their prevalence, clinical characteristics and associated outcomes in a real-life setting are unclear. Methods: To investigate them, we studied 3183 patients diagnosed with COPD by their attending physician included in the NOVELTY study (clinicaltrials.gov identifier NCT02760329), a global, 3-year, observational, real-life cohort that included patients recruited from both primary and specialist care clinics in 18 countries. Results: We found that 1) approximately a quarter of patients diagnosed with (and treated for) COPD in real life did not fulfil the spirometric diagnostic criteria recommended by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), and could be instead categorised as pre-COPD (13%) or PRISm (14%); 2) disease burden (symptoms and exacerbations) was highest in GOLD 3-4 patients (exacerbations per person-year (PPY) 0.82) and lower but similar in those in GOLD 1-2, pre-COPD and PRISm (exacerbations range 0.27-0.43 PPY); 3) lung function decline was highest in pre-COPD and GOLD 1-2, and much less pronounced in PRISm and GOLD 3-4; 4) PRISm and pre-COPD were not stable diagnostic categories and change substantially over time; and 5) all-cause mortality was highest in GOLD 3-4, lowest in pre-COPD, and intermediate and similar in GOLD 1-2 and PRISm. Conclusions: Patients diagnosed COPD in a real-life clinical setting present great diversity in symptom burden, progression and survival, warranting medical attention.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.